This research demonstrates the role of mitochondrial hydrogen sulfide in metastatic breast cancer, suggesting improved tumor localization with advanced fluorescent probes.
Metastatic breast cancer (MBC) is the primary cause of breast cancer-related mortality, where mitochondrial H2S (Mito-H2S) serves as a key metastatic mediator. However, further understanding of Mito-H2S metabolism during metastasis remains limited, largely due to a lack of specific imaging probes. Additionally, the inherently low signal-to-noise (S/N) ratio of most fluorescent probes presents significant challenges for tumor localization and surgical resection. To address these, we developed an activatable near-infrared fluorescent probe (SCy-H2S) featuring triple-synergistic mitochondrial targeting: positive ζ-potential driven electrostatic interactions, high-affinity binding to membrane protein, and selective activation by Mito-H2S. Upon interaction with Mito-H2S, the probe exhibits a pronounced fluorescence turn-on, achieving a high S/N ratio for real-time tracking of Mito-H2S dynamics. Moreover, by exploiting the role of Mito-H2S, we elucidate the mechanistic relationship between Mito-H2S and mitochondrial ATP production during cancer progression. The probe successfully visualizes Mito-H2S upregulation during metformin-induced liver injury and breast cancer metastasis, enabling the accurate delineation of tumor margins for fluorescence-guided resection of liver metastases.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: